A Phase I Study of PiggyBac CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Persistent and Relapsed B-cell Leukaemia and Lymphoma Post Allogeneic Stem Cell Transplantation (The CARTELL Study). [ 2016 - 2018 ]

Research Grant

Researchers: Dr Kenneth Micklethwaite (Principal investigator) ,  A/Pr Tracey O'Brien ,  Dr Luciano Dalla-Pozza ,  Dr Toby Trahair ,  Prof David Gottlieb
View all 6 related researchers

Brief description Most people with relapsed leukaemia and lymphoma after bone marrow transplant die of their disease. Inserting special genes into immune cells can enable them to kill leukaemia and lymphoma and has led to dramatic cures, but there is little experience in bone marrow transplant patients. We will make leukaemia and lymphoma specific immune cells from normal bone marrow transplant donors, then administer the immune cells to transplant patients to assess their safety and effectiveness.

Funding Amount $AUD 367,696.08

Funding Scheme Project Grants

Notes Standard Project Grant